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BACKGROUND: Methylating agents such as N-methyl-N-nitrosourea (MNU) can cause cell cycle arrest and death either via caspase-
dependent apoptosis or via a poly(ADP-ribose) polymerase (PARP)-dependent form of apoptosis. We wished to investigate the
possible role of MLH1 in signalling cell death through PARP.
METHODS: Fibroblasts are particularly dependent on a PARP-mediated cell death response to methylating agents. We used hTERT-
immortalised normal human fibroblasts (WT) to generate isogenic MLH1-depleted cells, confirmed by quantitative PCR and western
blotting. Drug resistance was measured by clonogenic and cell viability assays and effects on the cell cycle by cell sorting. Damage
signalling was additionally investigated using immunostaining.
RESULTS: MLH1-depleted cells were more resistant to MNU, as expected. Despite having an intact G2/M checkpoint, the WT cells did
not initially undergo cell cycle arrest but instead triggered cell death directly by PARP overactivation and nuclear translocation of
apoptosis-inducing factor (AIF). The MLH1-depleted cells showed defects in this pathway, with decreased staining for phosphorylated
H2AX, altered PARP activity and reduced AIF translocation. Inhibitors of PARP, but not of caspases, blocked AIF translocation and
greatly decreased short-term cell death in both WT and MLH1-depleted cells. This MLH1-dependent response to MNU was not
blocked by inhibitors of ATM/ATR or p53.
CONCLUSION: These novel data indicate an important role for MLH1 in signalling PARP-dependent cell death in response to the
methylating agent MNU.
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Mismatch repair (MMR) is an essential system for reducing
postreplicative errors in DNA including base–base mispairs and
small insertion/deletion loops due to polymerase slippage, and is
conserved from bacteria to humans. In E. coli it consists of two key
homodimeric proteins: MutS, which recognises and binds the
mismatch, and MutL, which is recruited to the complex and
initiates repair (Kunkel and Erie, 2005). In humans there are
multiple homologues for each protein and they combine to form
alternative repair complexes with slightly different specificities:
MutSa, a heterodimer of MSH2 and MSH6, can bind single base
mismatches or insertion/deletion loops, whereas MutSb, a hetero-
dimer of MSH2 and MSH3 only binds to insertion/deletion loops
(Kunkel and Erie, 2005). For somatic cells, the primary MutL
complex is called MutLa and consists of a heterodimer of MLH1
and PMS2, which binds to MutS and initiates repair (Raschle et al,
2002). Excision of the damaged base and resynthesis involves
participation of other proteins such as PCNA, EXO1 and DNA
polymerases d and e (Kunkel and Erie, 2005). In the absence
of functional MMR, high rates of mutation are seen, particularly
at microsatellite repeats, which can lead to inactivating frame-
shifts in mononucleotide runs within the coding regions of
genes such as BLM, BAX and IGFIIR, disrupting their function
(Duval and Hamelin, 2002). This mutator phenotype also
complicates the separation of primary and secondary effects of
MLH1-deficiency.
Mutations or epigenetic silencing of MMR genes is associated
with several human cancers. Lynch Syndrome, or hereditary non-
polyposis colorectal cancer, arises as a result of a primary defect in
MMR genes, most commonly MLH1 and MSH2 (Peltomaki and
Vasen, 2004); patients have a very high risk of developing
colorectal and/or endometrial tumours and are at elevated risk
for certain other types of tumours. Defects in MMR are also found
in sporadic cancers of the colon, stomach, endometrium and ovary
(Thibodeau et al, 1998). For most sporadic cancers, inactivation of
MLH1 is usually associated with methylation of the promoter
rather than mutation (Herman and Baylin, 2003). MMR-defective
tumours can also arise in response to exposure to some cytotoxic
agents, with microsatellite instability being reported in lung cancer
in chromium-exposed workers (Hirose et al, 2002) and in
glioblastomas after temozolomide treatment (Cahill et al, 2007).
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MMR-deficient cells show resistance to a number of different classes
of chemotherapeutic drugs (reviewed in O’Brien and Brown, 2006)
such as the methylating agent N-methyl-N-nitrosourea (MNU), the
cross-linking agent cisplatin and the antimetabolite 6-thioguanine
(6TG). MLH1 has been shown to participate in signalling cell cycle
arrest in response to 6TG and MNU, or to the related methylating
agent N-methyl-N0-nitro-N-nitrosoguanidine (MNNG; Hawn et al,
1995; Buermeyer et al, 1999). For MNNG, MLH1 signals arrest in
conjunction with the phosphatidylinositol 3-kinase-like kinases
Ataxia telangiectasia mutated (ATM; Adamson et al, 2005) and
ATM- and Rad3-related (ATR; Stojic et al, 2004). These kinases
phosphorylate a number of targets in the cell in response to
damage, such as the variant histone H2AX and p53 (Lavin et al,
2005). Treatment of cells with MNNG (Yanamadala and Ljungman,
2003) also leads to stabilisation of p53 and subsequently triggers
apoptosis through a caspase-mediated pathway, which is dependent
on MLH1 (Hickman and Samson, 1999, 2004; Yanamadala and
Ljungman, 2003). This pathway is primarily important in cells
which are deficient in methylguanine methyltransferase (MGMT),
indicating that the main cytotoxic lesion caused by the methylating
agents is 0
6-methylguanine (Hickman and Samson, 2004). More
recently, MLH1 has been shown by Kinsella and co-workers to be
important for signalling autophagy and inhibiting apoptosis in
response to 6TG, a pathway that also requires p53 (Zeng et al, 2007).
The damage signalling function of MLH1 has been shown to require
higher levels of the protein than those needed to successfully
maintain microsatellite stability, as cells with low levels of MLH1
show no increase in mutation rate but have lost the ability to signal
cell cycle arrest in response to 6TG (Buermeyer et al, 1999) or
MNNG (Buermeyer et al, 1999; Cejka et al, 2003; Stojic et al, 2004).
Methylating agents are in widespread use in chemotherapy, in
part, due to their ability to kill apoptosis-resistant cells such as
follicular lymphoma (Lister, 1991; Zong et al, 2004; Amaravadi and
Thompson, 2007). Cells that express the oncogene bcl-2, a dominant-
negative regulator of apoptosis, or which are deficient in the cellular
homologues BAK or BAX, are resistant to apoptosis through caspase-
mediated pathways (Danial, 2007). Methylating agents can trigger an
alternative cell death pathway in Bax/Bak double mutant mouse
fibroblast cells (Zong et al, 2004; Moubarak et al, 2007), or in cells
overexpressing bcl-2 (Amaravadi and Thompson, 2007), involving
poly(ADP-ribose) polymerase (PARP). PARP is a nuclear enzyme,
which responds to DNA damage by adding 50–200 molecules of
ADP-ribose to a variety of nuclear targets, including histones (Kim
et al, 2005). PARP activation causes a rapid drop in nicotinamide
adenine dinucleotide (NADþ) levels, triggering mitochondrial
membrane depolarisation and translocation of apoptosis inducing
factor (AIF) to the nucleus (Yu et al, 2002, 2006). In the nucleus, AIF
causes chromatin condensation and DNA fragmentation (Susin et al,
1999). However, little is known about the upstream signalling events
which activate PARP in response to methylating damage.
Here we sought to address the possible role of MLH1 in caspase-
independent programmed cell death in response to methylating
agents. We generated an isogenic system of normal human
fibroblasts and derivatives, which are MLH1 depleted and resistant
to MNU, but lack complications such as microsatellite instability
and aneuploidy. We show here that the WT cells initially die
almost exclusively by PARP-mediated cell death, and that this
pathway is inhibited in cells with decreased levels of MLH1. These
data uncover a new role for MLH1 in regulating a caspase-
independent, non-autophagic mechanism for cell killing.
MATERIALS AND METHODS
Cell culture and drug treatment
The colon cancer cell lines HCT116 and HCT116þchromosome 3
(HCTþchr3) cells (Koi et al, 1994) were maintained in DMEM
with 10% FBS; the latter were cultured with 400mgml
 1 G418
periodically to ensure retention of the extra chromosome 3. The
normal (WT) human fibroblast cell line hTERT-1604 (Ouellette
et al, 2000) with a stably integrated (CA)17 microsatellite repeat
(Roques et al, 2001) and their MLH1-depleted derivatives (M1, M2,
etc) were grown in high-glucose DMEM with 10% FBS and 2 
non-essential amino acids, with hygromycin (150mgml
 1) for the
siRNA-containing cells. Selection was removed 48h before any
experimental analysis. For MNU (Sigma, Poole, UK) treatment,
cells were pretreated with 25mM 0
6-benzylguanine (BG; Sigma) to
inactivate MGMT and BG was kept in the medium throughout.
Other inhibitors were maintained in the media as follows: 3,4-
dihydro-5[4-(1-piperindinyl)butoxy]-1(2H)-isoquinoline (DPQ;
Sigma) at a final concentration of 30mM (Yu et al, 2002); Boc-D-
FMK at 10mM (Hickman and Samson, 2004); caffeine at 2mM
(Stojic et al, 2004) and pifithrin at 20mM (Zeng et al, 2007).
Treatment with MNU was for 2h in all cases: apart from the colony
assays, where different concentrations were used, all other
experiments used 2mM MNU. For 6TG (Sigma), medium was
changed every 48h with the drug present throughout. For
hydroxyurea (Invitrogen, Paisley, UK), cells were treated at 5mM
for 72h (Jiang et al, 1999).
Stable RNAi vector assembly and transfection
An siRNA oligonucleotide MLH1-1733 50-AACTGTTCTACCAGA
TACTCATT-30 was designed for MLH1 using an algorithm (Yuan
et al, 2004; available at http://jura.wi.mit.edu). Overlapping
primers incorporating the siRNA sequences were made and ligated
into pSilencer (Ambion, Huntingdon, UK) as per the supplier’s
recommendations. All constructs were verified by sequencing. The
vector was linearised (SalI) and 1 10
7 cells electroporated
(BioRad GenepulserII; Bio-Rad Laboratories Inc., Hemel
Hempstead, UK) with 1mg of construct in PBS at 320V and
500mF. Medium containing serum was immediately added and the
cells plated on 90mm dishes at 5 10
5 cells per dish before
selection in hygromycin (150mgml
 1) for 10–14 days.
Western blotting
Total protein (30mg) from cells growing in log phase was
resolved by SDS–PAGE, electroblotted onto nitrocellulose
membranes and blocked for 2h at room temperature (RT) in 5%
non-fat dry milk. Membranes were incubated with anti-MLH1
(BD Pharmingen; G168-15, Oxford, UK), anti-b-actin (Abcam;
8226, Cambridge, UK), anti-PMS2 (BD Pharmingen; A16-4), anti-
GAPDH (Cell Signaling Technologies; 14C10, Herts, UK),
anti-Caspase 7 (Cell Signaling Technologies; 9492), anti-PARP
(BD Pharmingen; 4C10-5) or anti-PAR (BD Pharmingen; LP96-10)
overnight at 41C, followed by HRP-conjugated secondary antibody
for 2h at RT before detection using ECL (Amersham Biosciences,
Amersham, UK).
Table 1 Primer sequences and PCR product sizes for RT–PCR
Gene Primers Product size (bp)
MLH1 F: 50-TGGGACGAAGAAAAGGAATG -30 250
R: 50-GATCAGGCAGGTTAGCAAGC-30
MSH6 F: 50-GCACGAGTGGAACAGACTG-30 430
R: 50-CGGGTATCAGACCTTCCTG-30
PMS1 F: 50-CACTTCGGTGGTCAGTGTTG-30 713
R: 50-GATGAAACTTCTTTCTGGTGTTG-30
PMS2 F: 50-CCCATGGTAGAAAAGCAGC-30 533
R: 50-GCGAGATTAAGTTGGCTGAG-30
MSH2 F: 50-GCTGGAAATAAGGCATCCA-30 441
R: 50-CATCTGCTCTCCCTTTTTG-30
ACTB F: 50-AACTGGAACGGTGAAGGTG-30 350
R: 50-TCAAGTTGGGGACAAAAG-30
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Total RNA was extracted using the RNeasy kit (Qiagen, Crawley, UK)
and cDNA made using oligo d(T)15 and reverse transcriptase
(Promega, Southampton, UK). The Taqman gene expression assay
kit was used for quantitative PCR (QPCR) of MLH1 (Applied
Biosystems, Warrington, UK) with preincubation at 951Cf o r1 0m i n ,
then 40 951C for 15s and 601Cf o r1 m i n .MLH1 values were
normalised to GAPDH.T h e2
 DDCT method (Bustin, 2000) was used
to quantify the fold difference in MLH1 expression between WT and
knockdown and the assay repeated three times. PCR was carried out
on cDNA using 1.25U Taq, 1  buffer, 3.5mM MgCl2,0 . 4m M dNTPs
and 0.5pmol primer (Invitrogen) at 941C for 3min, then 25  941C
for 1min; 601Cf o r1m i n ;6 8 1C for 1min and finally 721Cf o r1 0m i n .
For primer sequences and product sizes see Table 1.
Cell viability and senescence assays
TUNEL staining was done using the in situ Cell Death Detection
Kit (Roche, Burgess Hill, UK) following the manufacturer’s
instructions and counterstaining with DAPI (125ngml
 1). An
ethidium bromide/acridine orange staining technique visualised
cells which were undergoing late apoptosis or necrosis (Ribble
et al, 2005), which appear red in both cases. Slides were prepared
in duplicate and three independent experiments performed. For
senescence associated b-galactosidase assays, 1 10
5 cells per well
were seeded on six-well plates and allowed to attach overnight,
followed by MNU treatment. Number of senescing cells was
determined as described (Rambhatla et al, 2002); as a positive
control the solution was buffered to pH4 to detect non-specific
lysosomal b-galactosidase activity.
Cell cycle profile analysis
1 10
6 cells in log phase were harvested, resuspended in 2ml ice-
cold 70% ethanol and stored at  201C for a minimum of 30min.
They were then centrifuged at 300g for 5min, resuspended in 400ml
PBS and passed through a 25-gauge needle. To this, 50mlo f
1mgml
 1 RNase and 50mlo f4 0 0 mgml
 1 propidium iodide was
added. This was incubated for 30min in the dark at 371C and placed
on ice before counting on a Becton Dickinson (Oxford, UK)
FACScalibur II.
Microsatellite mutation rate analysis
The fluctuation analysis was performed as previously described
(Roques et al, 2001) with the number of revertants in each
subculture corrected for colony-forming efficiency. Mutation rates
were calculated using the Luria–Delbruck method of the mean and
statistical analysis was as described (Roques et al, 2001).
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Figure 1 MLH1 depletion in the hTERT-1604 human fibroblast cell line. (A) Western blot of total protein from the parental hTERT-1604 cells used for
the transfections (WT) and the clonally derived cell lines M1, M2 and M3 each containing a stably integrated MLH1 siRNA vector. Scr denotes cells which
contain a scrambled siRNA as negative control. Antibodies used are indicated at left: b-actin is a loading control. (B) Quantitative PCR (QPCR) showing
MLH1 transcription levels in clones compared to WT. Samples were normalised to GAPDH and values represent the mean of each experiment ±2
standard deviations (s.d.). RNA from the cell with the scrambled control (Scr) is the negative control. (C) Western blot from the indicated cell lines. The
same membrane was probed in succession for each of the antibodies at right. A colon cancer cell line lacking MLH1 (HCT116) and the derived cell line
HCT116þchr3 containing MLH1 (HCTþchr3) are shown as controls: GAPDH is a loading control. (D) RT–PCR for each of the MMR genes indicated in
WT and M1 cells. b-Actin (ACTB) and a reverse transcriptase negative (RT ve) sample are positive and negative controls, respectively; the arrow indicates
the 500bp band on the size ladder. (E) Western blot of protein extracts from M1 cells grown in the absence of hygromycin (no selection): passage number
(P) is indicated. Controls are as in (C). The experiments in (A–D) were carried out at least three times and experiment (E) twice.
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Cells were seeded at 500 cells per 100mm dish and after recovery
for 24h were treated with drugs as indicated above. After 14 days,
plates were stained with crystal violet and colonies counted;
numbers were expressed as a percentage of the colonies formed in
the absence of the drug. Assays were carried out in triplicate and
three independent experiments were completed.
Immunofluorescence
Gelatin-coated superfrost slides (BDH, Poole, UK) were sterilised
by UV overnight, placed in quadriPERM chamber dishes (Sigma),
seeded with 5 10
5 cells and then left overnight again. Drug
treatment was as described above. Slides were washed for 3 5min
in PBS and fixed for 15min in 4% ice-cold paraformaldehyde, then
washed 3 5min in AB buffer (1% triton X-100, 4% goat serum,
0.2% SDS in PBS). Blocking and permeabilisation was in AB buffer
for 3h before incubation overnight with mouse anti-phospho
H2AX antibody (Upstate, Watford, UK) at 1:300 dilution, or with
rabbit antiapoptosis inducing factor (Cell Signaling Technologies)
at 1:150 in AB buffer at 41C. Slides were then rinsed in AB buffer,
3 5min and incubated with goat anti-mouse or anti-rabbit Alexa
Fluor 488 (Molecular Probes, Eugene, OR, USA) at 1:400 for 1h at
RT, then rinsing as before. Counterstaining was with Hoescht DNA
stain (Sigma) before mounting in Vectashield. Images were
captured on a Two-photon Laser Scanning Microscope (Leica,
Milton Keynes, UK). Experiments were carried out three times;
pictures taken are representative of each slide at each time point.
Statistical analysis
Results, unless noted, are presented as mean±standard deviation
(s.d.) for a given number of observations (n). Data from each set of
observations were cross-compared using unpaired Student’s t-tests
(GraphPad Prism software, GraphPad Software Inc., La Jolla, CA,
USA). Differences were considered significant if Po0.05.
RESULTS
Initial characterisation of fibroblast cell lines depleted in
MLH1
Human hTERT-1604 fibroblast cells (WT) were transfected with
a vector expressing an siRNA specific for MLH1 and individual
resistant colonies picked following growth in hygromycin. Western
blotting was used to determine the MLH1 protein levels. Clones
varied in the extent of MLH1 depletion, presumably because of
insertion site effects. Two clones with low (M1 and M2) and one with
intermediate (M3) levels of MLH1 protein were analysed further
(Figure 1A), together with cells transcribing a scrambled control
(denoted Scr). Real-time PCR was carried out to confirm that the
decrease in MLH1 was due to reduced mRNA levels and not an effect
on translation and to provide accurate quantitation: levels in M1
(11.6%) and M2 (22.2%) were substantially decreased compared to
wild type (Figure 1B), whereas those in M3 cells were intermediate to
high (78.5%), with Scr cells (93.30%) essentially wild type (WT).
PMS2 forms the MutLa repair complex with MLH1 and requires
MLH1 binding for stability (4, 27). M1 cells showed decreased
PMS2 levels as seen in the MLH1-deficient cell line HCT116
(Figure 1C). Levels of PMS2 in M2 and M3 clones were comparable
to those of MLH1 in those cells (not shown). To ensure that there
was no non-specific targeting of PMS2 or other repair components
by the siRNA, we carried out reverse transcriptase–PCR
(Figure 1D) which shows that transcript levels for MSH6, PMS2,
PMS1 and MSH2 were unaffected.
To ensure that the clones identified are indeed depleted in
MLH1 because of the presence of the siRNA and not due to picking
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Figure 2 Drug resistance in MLH1-depleted cells. (A) Summary of
clonogenic assay results in response to 6TG. A total of 500 cells were
seeded on each plate and exposed to the indicated concentrations of the
drug for 14 days. Plates were stained and the number of colonies formed
expressed as a percentage of the number seen on an untreated plate.
Values represent the mean of two independent experiments with two
plates per cell line: error bars indicate ±s.d. HCT116 is a positive control.
M1 and HCT116 survival at 7.5mM was compared to WT; ***Po0.001.
(B) Examples of clonogenic assay plates for WT (left) and M1 (right) cells
following exposure to the indicated levels of MNU. (C) Summary of
clonogenic assays in response to MNU. HCT116 is a positive control;
HCTþchr3 and Scr are negative controls. Statistical comparisons are
between matched cell lines (HCT116 vs HCTþchr3 or WT vs M1 etc).
Values represent the mean of three independent experiments, each with
three plates per cell line: error bars indicate ±s.d.; ***Po0.001;
****Po0.0001. M1 and M2 gave similar P values at 2mM MNU. The Scr
cells were not significantly different from WT.
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carried out long-term culturing of M1 cells in the absence of
selection for the knockdown construct. This led to a gradual
increase in MLH1 levels due a slight growth advantage for cells
which have turned off siRNA expression. By passage 34 in the
absence of hygromycin, MLH1 levels were significantly higher
(Figure 1E), showing that MLH1 depletion can be reversed. This
was accompanied by increased PMS2 levels, thus restoring the
MutLa complex (Figure 1E); these cells were termed M1-R
(for ‘rescue’).
MLH1-deficiency increases cell survival in response to 6TG
and MNU
Resistance to 6TG is characteristic for cell lines lacking MLH1, and
M1 cells were as tolerant to 6TG as HCT116 cells by clonogenic
assay (Figure 2A). To test the tolerance of the different MLH1-
depleted lines to methylating agents, we exposed the cultures to
MNU. WT cells were sensitive to MNU only in the presence of
BG, which inhibits the endogenous MGMT activity, confirming
that the main cytotoxic lesion being caused by the drug was
0
6-methylguanine (Hickman and Samson, 2004). Figure 2B shows
typical results for MNU treatment in the presence of the inhibitor,
clearly illustrating the increased relative survival of the M1 cells.
Results for all the cell lines for MNU are summarised in Figure 2C:
resistance was similar in M1 and M2 cells, but the scrambled
control was indistinguishable from WT. M1-R cells showed similar
drug resistance as WT cells (not shown).
Previous studies have indicated that small amounts of MLH1 are
enough for normal repair of microsatellites, whereas much higher
levels of this protein are required for damage signalling to be
functional (Buermeyer et al, 1999; Cejka et al, 2003). We found the
same to be true of our MLH1-depleted cell lines. To test mutation
rates, we carried out a Luria–Delbruck fluctuation test (Supple-
mentary Figure 1A) in the M1 cell line, taking advantage of a
(CA)17 microsatellite reporter with a downstream neo gene in the
( 1) reading frame which was inserted in the WT cells (Roques
et al, 2001). The neo gene can be brought back in frame by deletion
of a single repeat ( 2bp) or insertion of two repeats (þ4bp) in
the microsatellite, though larger insertions/deletions are possible.
The types of mutations were determined by capillary electrophor-
esis of fluorescently labelled PCR products (Supplementary Figure
1B). Overall, the microsatellite mutation rates were not signifi-
cantly different between the M1, WT and Scr cells (Table 2).
The relative frequencies of the different type of mutations seen are
also summarised in Supplementary Figure 1C and suggest no
change in the mutational spectrum in M1 cells. These results
confirm that the effects we are seeing in M1 cells are due to the loss
of the damage signalling function of MLH1 only, as there is no
discernable difference in microsatellite repair function compared
to WT cells.
Absence of initial cell cycle arrest in response to MNU in
WT hTERT-immortalised cells
For most mouse fibroblast or human cancer cell lines, exposure to
methylating agents leads to G2/M arrest after two cell divisions and
in an MLH1-dependent manner (Hawn et al, 1995; Aquilina et al,
1999; Buermeyer et al, 1999). WT fibroblasts did not arrest out to
96h (Figure 3A), however, at doses of MNU which gave significant
differences in survival (see Figure 2A and B). We could confirm
MLH1-dependent cell cycle arrest by 48h in HCT116 and
HCT116þchr3 (Figure 3A), where the MLH1
þ cells arrest in the
second cell cycle after exposure (Cejka et al, 2003; Stojic et al,
2004), whereas the MLH1-deficient HCT116 do not. Similar results
were found for 6TG: HCT116þchr3 arrested, but WT did not. M1
cells, like WT cells, did not arrest for either drug (not shown). All
experiments were repeated at least three times. Telomerase-
immortalised fibroblasts have previously been shown to have
normal cell cycle arrest in response to various insults (Jiang et al,
1999; Vaziri et al, 1999; Ouellette et al, 2000) and we could confirm
that the cells have an intact G2/M checkpoint, as they arrest at this
point in response to depletion of DNMT1 (Figure 3A; Chen et al,
2007). They also show G1 accumulation (Supplementary Figure 2A)
in response to 5-hydroxyurea (Jiang et al, 1999). Some cancer cells
can enter senescence with only transient arrest in response to
methylating agents (Hirose et al, 2001, 2002) and hTERT-
immortalised cells can exit the cell cycle and enter senescence in
response to stresses such as serum deprivation (Hirose et al, 2002;
Rambhatla et al, 2002), but we found no increase in the number of
senescing cells in response to MNU (Supplementary Figure 2B).
WT cells show a strong MLH1-dependent H2AX
phosphorylation response to MNU exposure
Mismatch repair-coupled processing of methylation damage leads
to single-strand DNA breaks, which become sites for H2AX
phosphorylation (Cejka et al, 2003; Mojas et al, 2007). This can be
seen in HCT116þchr3 cells, which show stronger and more
persistent H2AX phosphorylation by 48h (Figure 3B) than
HCT116, as reported previously (Cejka et al, 2003; Mojas et al,
2007; 12, 24, 48 and 72h time points also examined; data not
shown). WT cells also showed phosphorylation of H2AX at 48h
(Figure 3B), indicating that the cells are indeed detecting the
MNU-induced damage in a similar timeframe to the colon cancer
cells. Signalling in the WT fibroblasts appeared more widespread
Table 2 Rate of mutation of reporter (CA)17 repeat in MLH1-depleted cells (M1) and controls
Cell line
Mean cloning
efficiency
Mean G418 resistant
colonies per plate
Proportion of colonies with
microsatellite frameshifts
Microsatellite mutation rate
(mutations per cell per generation)
0.51 5 1 1.11 10
 5
WT 0.52 9 1 1.56 10
 5
0.48 11 0.81 1.78 10
 5
0.39 20 0.77 6.64 10
 6
M1 0.49 14 0.95 1.78 10
 5
0.48 16 1 5.63 10
 5
0.5 4 1 9.2 10
 6
Scr 0.56 9 1 1.15 10
 5
0.51 6 0.9 1.4 10
 5
For mutation rate analysis, the colony forming efficiency with respect to unselected controls, number of resistant clones, and the fraction of clones with a frameshift in the
microsatellite region were determined. Each line represents the respective value for three independent experiments, with median values for the mutation rates indicated in bold.
(ie, three replicates   three independent experiments for WT gave an overall median mutation rate for all nine samples of 1.56 10
 5). The difference between the median
values for the three groups is not statistically significant (M1 vs WT, P¼0.4705; Scr vs WT, P¼0.2468).
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sand intense than in HCT116þchr3, suggesting a stronger response
in these normal cells (experiments were repeated three times). M1
cells showed much lower levels of phosphorylation, indicating that
MLH1 depletion prevents normal H2AX signalling in response to
MNU in the fibroblasts as well. Confirming that this is due to the
absence of MLH1 alone, rescued cells with restored MLH1 levels
Untreated Untreated
MNU
48 h
MNU
96 h
Untreated
+DNMT1
RNAi
MNU
48 h
Untreated
MNU
48 h
HCT116
DNA H2A.X Merge
HCT+chr3
M1
WT
M1-R
HCT116
WT HCT+chr3
G1 SG 2
G1SG 2
G1 SG 2
G1 SG 2
G1 SG 2
G1 SG 2
G1 SG 2
G1 SG 2
Figure 3 Cell cycle profiles and H2AX signalling in WT and MLH1-depleted cells. (A) Cell cycle profiles. Analysis of WT cells which were exposed to
2m M MNU for 2h or left untreated, then grown in normal medium, harvested after the indicated time, stained with propidium iodide and analysed by flow
cytometry (left). The G1, S and G2/M fractions are indicated. WT cells arrested in G2/M by depletion of DNMT1 (DNMT1 RNAi) are shown as a control.
HCT116 and HCT116þchr3 (HCTþchr3) are also shown as controls (right). (B) Cells from the cell lines indicated at left were grown on slides and fixed
at 48h after 2mM MNU treatment before carrying out immunofluorescence with antibody to the phosphorylated form of histone H2AX (green). DNA was
counterstained with Hoescht (blue) to localise the nuclei and images captured on a confocal microscope using identical settings: merged images are shown at
right. Experiments were carried out at least three times each.
Figure 4 Differences in PARP activity and in viability between WT and MLH1-depleted cells. (A) Cell viability was assayed using ethidium bromide/
acridine orange staining, which detects both apoptotic and necrotic cells. WT and M1 cells were treated with MNU as indicated and numbers of dying cells
counted at the times shown. As a control, cells treated with camptothecin were assayed at 72h. Values represent the mean of three replicates ±s.d.;
*Po0.05; ****Po0.0001. The experiment was carried out at least three times. (B) WT and M1 cells were treated with 2mM MNU and protein extracted
at the indicated times for western blotting with the antibodies shown at left. The asterisk indicates a background band for this antibody also seen in other
studies. GAPDH is shown as a loading control. Extracts from cells 48h after treatment with staurosporine (STS), which triggers PARP cleavage, are shown
for comparison. Experiments were carried out twice. (C) WT or M1 cells were seeded onto slides, treated with 2mM MNU and grown for 48h before
fixing and examining for nuclear or cytoplasmic localisation of AIF (green) by immunofluorescence on a confocal microscope. DNA was counterstained with
Hoescht (blue) and merged images are shown at right. DPQ (30mM) is a PARP inhibitor and Boc-D-FMK (10mM) a pan-caspase inhibitor. Experiments were
carried out three times. (D) Quantitative analysis of the effects of MNU and inhibitors on AIF localisation, based on scoring immunofluoresence staining as
seen in (C) for 4100 cells on multiple slides. (E) WT and M1 cells were treated with 2mM MNU, either alone or in combination with 30mM DPQ or 10mM
Boc-D-FMK, and analysed at 72h as in (A) above; values represent the mean of three samples ±s.d.; ***Po0.001; *Po0.05; ns, not significant. (F)
Clonogenic assays in response to 2mM MNU, 30mM DPQ or a combination of the two were carried out on the indicated cell lines with two plates per cell
line; error bars indicate ±s.d. values. The assay was carried out three times for the fibroblasts (WT and M1), with representative results shown, and once for
the controls (HCT116 and HCT116þchr3).
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srecovered the ability to strongly activate this damage signal (M1-R;
Figure 3B).
MLH1-dependent cell death involves activation of PARP,
but not caspases
Cell death can occur in the absence of cell cycle arrest under
certain circumstances (Peterson-Roth et al, 2005; Meador et al,
2008). Methylating agents can trigger cell death directly through
caspase- (Hickman and Samson, 2004) or PARP-mediated
(Yu et al, 2002) pathways. Using acridine orange/ethidium
bromide staining we found significant differences in viability by
48h between WT and MLH1-depleted cells treated with 2mM
MNU (Figure 4A). We examined PARP activity over time in the
MNU-treated cells by western blotting with an anti-PAR antibody
(Figure 4B). Increasing numbers of PAR-labelled proteins became
visible from 12 to 48h in the WT cells, but by 72h substrate
seemed to have been exhausted as almost no PAR groups were
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sdetected. In M1 cells however, PAR levels were barely detectable at
12h, lower than WT at 48h and were still easily detectable at 72h
(Figure 4B). These results suggested that PARP was being activated
in response to the MNU-induced damage and that activation
depended in part on MLH1. In contrast, no evidence of caspase
activation was seen at these time points: targets of caspase cleavage
such as caspase-7 and PARP-1 itself remain uncleaved throughout
this period (Figure 4B). PARP-1 cleavage in response to
staurosporine, a known initiator of caspase-mediated cell death,
is shown for comparison. Likewise, we could detect no evidence for
TUNEL staining in WT or MLH1-depleted cells during this period
(Table 3).
PARP overactivation can lead to translocation of apoptosis-
inducing factor (AIF) from the mitochondrion to the nucleus (Yu
et al, 2002, 2006). We examined AIF localisation in WT and MLH1-
depleted cells (Figure 4C). In untreated WT cells, AIF was present
in the cytoplasm in a speckled pattern consistent with its normal
mitochondrial localisation; 48h after treatment with MNU,
most AIF can instead be found in the nucleus of the WT cells.
In contrast, M1 cells show little or no nuclear staining 48h after
MNU treatment (Figure 4C). To confirm that translocation was
dependent on PARP, we treated the WT cells with the PARP
inhibitor DPQ as well as MNU: in the presence of DPQ, almost no
AIF translocation was seen (Figure 4C). DPQ had no effect on AIF
localisation in M1 cells, where it remained cytoplasmic. Substitut-
ing a general caspase inhibitor (Boc-D-FMK) instead of DPQ did
not block AIF translocation (Figure 4C). Quantitative analysis
confirms that MLH1 depletion reduced AIF translocation in
response to MNU (Figure 4D) and that translocation is also
dependent on PARP, but not caspase activity.
To examine whether inhibiting these events would lead to
decreased cell death in response to MNU, we examined cell
viability following DPQ treatment. The addition of the PARP
inhibitor with MNU led to almost complete abrogation of the
short-term effects of MNU on cell viability in both WT and M1
cells (Figure 4E), confirming that MNU initially kills these cells
almost exclusively by a PARP-dependent mechanism and that the
residual sensitivity to MNU in M1 cells (which may be due to the
remaining MLH1) can be overcome by blocking PARP activity.
However treatment of cells with DPQ leads to a potentiation of cell
killing in response to 2mM MNU in a clonogenic assay, compared
to treatment with MNU alone (Figure 4F), as previously reported.
This is normally attributed to the detrimental effects of PARP
inhibition in the long term on BER-mediated repair of MNU-
induced damage, but may also be partly due to its inherent
cytotoxicity, evident in cells treated with DPQ alone (Figure 4F).
PARP activation and AIF translocation have been shown to lead to
mitochondrial membrane depolarisation, cytochrome c release and
subsequent caspase activation (Yu et al, 2002). In keeping with
this, we found that caspase inhibitors could partly reduce cell
death in the WT cells at 72h (Figure 4E, Po0.05). Significantly,
caspase inhibitors had no protective effect in MLH1-depleted cells,
as levels of cell death were unchanged from those seen in cultures
treated with MNU alone, suggesting that in the absence of PARP-
mediated AIF translocation, no caspase activation is occurring.
MLH1, but not ATM/ATR or p53, is required for
PARP-mediated cell death in response to MNU
In colon cancer cells, MLH1 requires ATR (Stojic et al, 2004) and
ATM (Adamson et al, 2005) to phosphorylate H2AX and to signal
cell cycle arrest, but does not require WT p53 for either process
(Cejka et al, 2003); however, MLH1 does require p53 to mediate an
autophagic response to 6TG (Zeng et al, 2007). On treating our WT
cells with caffeine, an ATM/ATR inhibitor, we found that little
H2AX phosphorylation could be detected (Figure 5A). Pifithrin, a
p53 inhibitor, gave some reduction in signal, but not as much as in
MLH1-depleted cells (Figure 5A).
To determine if inhibiting ATM/ATR would also prevent AIF
translocation, we examined protein localisation in caffeine-treated
cells. Using a concentration of inhibitor, which effectively blocked
H2AX phosphorylation, we still saw AIF translocate to the nucleus
in the majority of cells examined (Figure 5B). Likewise, treatment
with the p53 inhibitor failed to block AIF movement in response to
MNU in most cells, though a fraction of cells showing cytoplasmic
retention of AIF was consistently seen (Figure 5B, arrows). In
keeping with these results, treatment of WT cells with caffeine or
with pifithrin caused a small but not statistically significant
decrease in cell death in response to MNU (Figure 5C). As before,
the MLH1-depleted cells showed no change in viability in the
presence of the ATM/ATR or p53 inhibitors, suggesting that in the
absence of MLH1 these cell death mediators are not substantially
activated (Figure 5C).
DISCUSSION
We show here for the first time that reductions in MLH1 levels
cause an impairment of PARP-mediated cell death in response to
MNU, implicating MLH1 as an important upstream activator of
this caspase-independent cell killing mechanism.
In keeping with previous findings (Buermeyer et al, 1999;
Cejka et al, 2003), low levels of MLH1 were sufficient to allow
maintenance of microsatellite stability in our cell lines but
insufficient to trigger a normal damage response to MNU or
6TG. The PARP-dependent cell death pathway, like some other
MLH1-mediated responses, therefore requires a higher level of
MLH1 protein than that needed for DNA repair.
Our results also show that cell death in response to MNU is not
necessarily preceded by G2/M arrest, because our WT cells show
no evidence of arrest well past the point at which significant
differences in cell signalling and cell survival are evident between
the MLH1-proficient and -depleted cells. Direct progression into a
cell death pathway without cell cycle arrest has been noted before
under some conditions where DNA damage is extensive (Hirose
et al, 2002) or H2AX signalling is affected (Meador et al, 2008). The
marked difference in the strength of H2AX signalling between our
WT fibroblasts and the HCT116þchr3 cells is a possible
explanation for the difference between these cell lines with regard
to cell cycle response. Previous work by a number of labs has
shown that cell cycle arrest in HCT116þchr3 is dependent on ATR
and ATM (Stojic et al, 2004; Adamson et al, 2005); in cells lacking
these proteins, H2AX phosphorylation is reduced and no arrest
occurs in response to MNU. ATM and PARP-1 have also been
Table 3 Percentage of WT and MLH1-depleted (M1) human fibroblasts
undergoing apoptosis in the presence of MNU
% Apoptotic cells (±s.e.m.)
DNase treated positive control (WT) 97.90 (±0.9)
WT
Untreated 1.51 (±0.5)
2m M MNU 12h 2.50 (±0.9)
2m M MNU 24h 1.48 (±0.5)
M1
Untreated 1.51 (±0.5)
2m M MNU 12h 1.58 (±0.4)
2m M MNU 24h 1.6 (±0.8)
Cells were seeded on poly-L-lysine slides and apoptosis measured by the TUNEL
method. Values shown are the mean percentage±s.e.m. of duplicate slides, counting
cells in 10 fields at  20 magnification. Three independent experiments were
conducted. The positive control was WT cells treated with DNaseI prior to the
addition of the terminal deoxynucleotidyl transferase.
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sshown recently to physically and functionally interact following
MNNG treatment (Haince et al, 2007). We could confirm that
ATM/ATR are also important for H2AX phosphorylation in our
cells, but that this signal was not required to trigger PARP-
mediated cell death, because blocking it could not prevent AIF
translocation or increase short-term viability.
The tumour suppressor p53 is a central integrator of stress and
cell damage responses and is mutated in almost half of all human
cancers. MLH1 triggers an autophagic response to 6TG, but cannot
do so if p53 is inactivated (Zeng et al, 2007). However, neither the
cell cycle arrest (Cejka et al, 2003) nor the caspase-mediated
apoptosis responses (Hickman and Samson, 1999), which MLH1
can invoke in some cells in response to MNU, appear to be p53-
dependent. We found that blocking p53 gave some reduction in
H2AX phosphorylation in response to MNU, but failed to prevent
AIF translocation or cell death in the majority of cells. These
results are consistent with other reports suggesting that the PARP-
mediated cell death pathway may be partially independent of
p53 (Zong et al, 2004; Moubarak et al, 2007).
Differences in H2AX phosphorylation between the WT and
MLH1-depleted cells are seen 48h after MNU treatment, as for
HCT116 and HCT116þchr3 cells (Cejka et al, 2003; Stojic et al,
2004), and are likely to be developing after the second round of
DNA replication. This is the same time point at which PARP
activity has peaked in WT fibroblasts and where differences in
viability are detectable between WT and MLH1-depleted cells. By
72h, PARP activity has fallen to zero in WT cells, suggesting
NADþ depletion, which is known to trigger AIF release from the
DNA H2AX DNA
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Figure 5 Effects of ATM/ATR and p53 inhibitors on PARP-mediated cell death. (A) H2AX phorphorylation (green) was examined using
immunofluoresence: nuclei were counterstained with Hoescht (blue). WT cells were treated with 2mM MNU for 2h as usual and allowed to recover in the
presence or absence of ATM/ATR inhibitor (2mM caffeine) or p53 inhibitor (20mM pifithrin). M1 cells are shown for comparison. Images are representative
of three independent experiments. Arrows indicate cells showing prominent nuclear staining in the presence of pifithrin. (B) AIF localisation was examined
using immunofluoresence to AIF (green) and counterstaining for DNA (blue); WT cells were treated with 2mM MNU and AMT/ATR inhibitor or p53
inhibitor as indicated in (A). Images are representative of three independent experiments. Arrows indicate cells showing prominent cytoplasmic staining in
the presence of pifithrin. (C) Cell viability was assayed following exposure of cells to 2mM MNU and ATM/ATR inhibitor (caffeine) or p53 inhibitor (pifithrin)
as before; values represent the mean of three samples ±s.d. There were no significant differences in viability in the presence of caffeine or pifithrin.
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smitochondrion (Yu et al, 2002; Zong et al, 2004; Moubarak et al,
2007). PARP activity in the MLH1-depleted cells is first evident at
48h at a lower intensity than in WT cells. Consistent with this, we
see far higher AIF translocation to the nucleus in WT cells
compared to the MLH1-depleted cells at this time. Up to this point,
no evidence of caspase activation can be seen: no protein cleavage,
TUNEL staining or sub-G1 fraction on FACS analysis were
detected. AIF translocation has been shown to lead to later
cytochrome c release and caspase activation (Yu et al, 2002;
Moubarak et al, 2007). Our results are also consistent with some
late activation of caspase-mediated cell death, but only in cells
where MLH1 is at WT levels and can first activate PARP. In a
previous study, Samson and colleagues found that although MLH1
was required to activate caspase cleavage in cells treated with a
methylating agent, cell death still occurs even in the presence of
caspase inhibitors or bcl-2 overexpression (Hickman and Samson,
2004). The data we present here suggest that PARP-mediated AIF
translocation is a candidate for the alternative cell death
mechanism triggered by methylating agents.
Although the PARP inhibitor DPQ decreased cell death in
response to MNU in the short term, it augmented the cell killing
effect of MNU in longer-term clonogenic assays. Both of these
effects have been well documented before (Tentori et al, 1999; Yu
et al, 2002; Curtin et al, 2004; Zong et al, 2004). This apparent
paradox can be resolved by considering the types of damage
induced by MNU and the two distinct responses, repair or cell
death, which can be triggered by PARP in the cell. MNU generates
a number of damaged bases in addition to 0
6-methylguanine,
mostly N-methylpurines, but these latter are promptly dealt with
by the base excision repair (BER) system. PARP facilitates BER by
catalysing the addition of PAR groups to histones, opening the
chromatin for BER access. If levels of damage are too high, PARP
becomes overactive and this depletes the cell of NAD, the substrate
for PAR, leading to mitochondrial membrane depolarisation and
eventual cell death (Yu et al, 2002; Zong et al, 2004). Inhibition of
PARP thus can block the early overactivation of the enzyme and
NAD depletion, leading to short-term gains in cell viability, but at
a cost to BER, the failure of which leads to the independent
triggering of cell death in the longer term by adducts such as
N
3-methyladenine (Engelward et al, 1998). Thus, combining PARP
inhibitors with MNU can help to kill MLH1-deficient cells, which
are resistant to 0
6-methylguanine, by instead making them
sensitive to the N-methylpurine damage. We did not see
preferential killing of MLH1-deficient vs MLH1-proficient colon
cancer cells (HCT116) or fibroblasts (M1) using DPQ and MNU, as
has been reported using temozolomide and second-generation
PARP inhibitors such as AG14361 (Curtin et al, 2004) or NU1025
(Tentori et al, 1999). These newer PARP inhibitors have lower
cytotoxicity and higher specificity than DPQ, which has non-
specific cytotoxic effects including interference with nucleoside
metabolism (Milam et al, 1986) and we show here that it has a
detrimental effect on long-term cell survival in the absence of
MNU.
MMR deficiency is an important clinical correlate of drug
resistance. The use of methylating agents such as temozolomide
can give rise to MMR-defective tumours following treatment of
ovarian (Brown et al, 1997) and brain tumours (Cahill et al, 2007)
and is an independent predictor of poor prognosis after
chemotherapy in breast (Mackay et al, 2000) and oesophageal
(Kishi et al, 2003) cancer patients. Our data indicate that MLH1-
deficient cells have a survival advantage against PARP-dependent
cell killing through AIF, as well as against caspase-mediated cell
death, which was previously known (Hickman and Samson, 1999,
2004). Examining the signalling pathway between MLH1 and PARP
may help in the design of strategies for overcoming chemother-
apeutic resistance caused by MMR defects. As epigenetic silencing
of the MLH1 promoter is commonly seen in tumours showing
acquired resistance (Herman and Baylin, 2003), our work also
suggests that combining strategies designed to reactivate the
silenced MLH1 (such as treatment with DAC; Plumb et al, 2000)
with SN1 methylating agents may promote PARP-mediated cell
death. This independent cell death pathway may be particularly
useful in cells where the caspase-mediated route has been blocked
due to microsatellite mutations at BAX or ATR (Bacon et al, 2001;
Mongiat-Artus et al, 2006). As MLH1 deficiency is sufficient to
confer resistance to a range of other clinically relevant chemother-
apeutic agents, including cisplatin and 6TG, our model system will
be of great use in determining whether MLH1 is involved in
signalling PARP in response to these agents as well.
In conclusion, our results show that MLH1 is required to induce
a caspase-independent cell death mechanism in response to the
SN1-type methylating agent MNU. This mechanism is independent
of the cell cycle response, ATM/ATR or p53 but is dependent on
PARP activation and subsequent AIF translocation.
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